Every promotional email, every HCP leave-behind, every PI summary passes through the same gauntlet. Medical. Legal. Regulatory. Revision. Repeat. Your MLR cycle isn't a process — it's a waiting room.
Brand team hands off data package
Agency writer researches & writes first draft
Brand manager feedback cycle
Medical affairs checks every claim
Regulatory counsel checks every statement
2.3 rounds of revisions on average
Final package assembled and submitted
43% of submissions require a second cycle
Prescribe doesn't accelerate the old process — it replaces it. The model reads your data, writes to your style guide, cites every claim, and hands your reviewer a complete MLR package before their first coffee.
Clinical endpoint, FDA ref, style guide loaded
Every assertion linked to an approved source
AMA-styled paragraph with inline citations
Claim matrix, source links, style compliance report
Submitted with zero ambiguous claims
Clinical trial CSRs, FDA guidance documents, prescribing information, and brand lexicons — loaded once, referenced on every draft.
No assertion appears without a traceable citation. The model refuses to generate unsubstantiated language — by design, not by prompt.
Alongside the copy, Prescribe generates a claim matrix with source references — the exact document your medical reviewer needs to approve in hours.
The model doesn't guess and check. It references first, writes second. Every claim is traceable before the sentence ends.
Prescribe won't write a sentence it can't source. The model is trained to refuse unsubstantiated language — not suppress it after the fact, but structurally prevent it at generation time.
Prescribe doesn't need a different model for oncology versus immunology. It adapts voice, terminology, and citation conventions to your therapeutic area — automatically.
Side by side. Human-drafted copy versus Prescribe output. Same brief. Radically different results.
"Keytruda has shown impressive results in breast cancer patients. In a major trial, patients who received Keytruda along with chemo did much better than those who just got chemo. The response rate was higher and patients lived longer without their cancer getting worse."
"Pembrolizumab plus chemotherapy demonstrated superior pathologic complete response (pCR) rates versus chemotherapy alone in patients with early-stage TNBC (64.8% vs 51.2%; HR, 0.63; 95% CI, 0.48–0.82; P<.001).[1][2]"
Ready to see your data become compliant copy?